We previously described a related and potentially targetable oncogenic mechanism in MLS that involves activation of the IGF1R‐PI3K‐AKT signaling cascade through FUS‐DDIT3‐dependent induction of IGF2 transcription (Trautmann et al, 2017). The gene discussed is IGF2; the disease is McLeod neuroacanthocytosis syndrome.